Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

Serina Therapeutics, Inc. ("Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, today congratulates its ...

Discover the new migraine medications, such as monoclonal antibodies and gepants, that are changing migraine treatment for ...

Two New Haven-based bioscience firms have announced an agreement to collaborate on research and development of therapies for ...

Biohaven Ltd. operates in the healthcare sector and is listed on the NYSE, with presence tracked across the broader Earnings Per Share. Activity surrounding the company recently drew attention through ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). Such investors are advised ...